China's COVID-19 inactivated vaccines available by 2020 end

Daniel Fowler
September 20, 2020

"The Belarusian Health Ministry has received the batch of documents for conducting clinical trials of the Gam-COVID-Vac vaccine (trade name Sputnik V)", the ministry wrote on Telegram.

"Sputnik V vaccine could provide a credible option in our fight against COVID-19 in India", he said.

Kirill Dmitriev, the CEO of RDIF, (Russian Direct Investment Fund ) - Russia's sovereign wealth fund that has been involved with developing the vaccine - says they are hopeful the approvals will come soon and the vaccine may be available this year itself in India.

Furthermore, Prasad said that the signs are good and their aim is to get the vaccine in the shortest period of time.

The Central Drugs Standard Control Organisation (CDSCO) informed that it had received information about one COVID-19 vaccine developed and approved in Russian Federation, minister of state for health Ashwini Choubey informed the Lok Sabha.

Russian Federation has billed Sputnik-V as the first vaccine against the coronavirus to be registered in the world.

NVIDIA Prepares to Buy ARM
SoftBank could receive up to $5 billion in cash or stock, subject to specific financial performance targets by Arm . "Our combination will create a company fabulously positioned for the age of AI ".

Around 100 volunteers will take part in the trials, the Belarusian Health Ministry added, calling on those wishing to join to submit applications on the websites of the eight health-care facilities in Minsk and Vitebsk where the trials will be held. According to Murashko, symptoms after being injected with the anti-coronavirus vaccine "level off" by the next day.

This is the first concrete development on Sputnik V after the Indian government confirmed it was in discussions to take forward the testing and manufacture of the candidate, which Russian Federation approved for public use last month.

The move drew major flak from the scientific community, with many experts claiming that premature approval, and the lack of full safety and efficacy data, could put people at risk. It is an adenovirus vector-based vaccine developed by the Gamalaleya National Center.

In a statement, DRL Co-Chairman and Managing Director G V Prasad said: "The phase 1 and 2 results have shown promise, and we will be conducting phase 3 trials in India to meet the requirements of the Indian regulators". "The platform of human adenoviral vectors, which is the core of the Russian vaccine, has been tested in more than 250 clinical studies over decades, and it has been found safe with no potential negative long-term consequences".

He also stated that the vaccine does not provide life-long immunity against the COVID-19 virus, but the vaccination can be repeated as needed.

With over 51 lakh cases and around 84,000 deaths so far, India is bearing the brunt of the novel coronavirus.

Other reports by

Discuss This Article